---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132307"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:54:57.943257+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting

## Summary
- Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.
- Ratified Ernst & Young as independent auditor for fiscal 2025 with 135,734,870 votes for.
- Approved repricing of certain outstanding stock options under 2020 and 2023 equity plans (101,589,422 for).
- Approved reverse stock split at ratio between 1:5 and 1:30, as determined by board (134,256,461 for).

## SEC filing metadata
- accession: 0001193125-25-132307
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/0001193125-25-132307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/d908298d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132307
- JSON: https://secwatch.observer/filing/0001193125-25-132307.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.